proposed a tumor fitness model based on immune interactions with neoantigens, identifying two key factors that determine neoantigen fitness, including the likelihood of neoantigen presentation by the major histocompatibility complex (MHC) and the subsequent recognition by T cells.[62] Collectively, these studies underscore the critical role of tumor‐antigen and T cell interactions in modulating responses to ICI therapies. The gene discussed is HLA-C; the disease is neoplasm.